Cargando…

Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma

BACKGROUND & AIMS: Although HBV is a major cause of death in Africa, its genetic variability has been poorly documented. This study aimed to address whether HBV genotype and surface gene variants are associated with HBV-related liver disease in The Gambia. METHODS: We conducted a case-control st...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Damien, Ghosh, Sumantra, Shimakawa, Yusuke, Ramou, Njie, Garcia, Pierre Simon, Dubois, Anaëlle, Guillot, Clément, Kakwata-Nkor Deluce, Nora, Tilloy, Valentin, Durand, Geoffroy, Voegele, Catherine, Ndow, Gibril, d'Alessandro, Umberto, Brochier-Armanet, Céline, Alain, Sophie, Le Calvez-Kelm, Florence, Hall, Janet, Zoulim, Fabien, Mendy, Maimuna, Thursz, Mark, Lemoine, Maud, Chemin, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452365/
https://www.ncbi.nlm.nih.gov/pubmed/32904132
http://dx.doi.org/10.1016/j.jhepr.2020.100144
_version_ 1783575145521086464
author Cohen, Damien
Ghosh, Sumantra
Shimakawa, Yusuke
Ramou, Njie
Garcia, Pierre Simon
Dubois, Anaëlle
Guillot, Clément
Kakwata-Nkor Deluce, Nora
Tilloy, Valentin
Durand, Geoffroy
Voegele, Catherine
Ndow, Gibril
d'Alessandro, Umberto
Brochier-Armanet, Céline
Alain, Sophie
Le Calvez-Kelm, Florence
Hall, Janet
Zoulim, Fabien
Mendy, Maimuna
Thursz, Mark
Lemoine, Maud
Chemin, Isabelle
author_facet Cohen, Damien
Ghosh, Sumantra
Shimakawa, Yusuke
Ramou, Njie
Garcia, Pierre Simon
Dubois, Anaëlle
Guillot, Clément
Kakwata-Nkor Deluce, Nora
Tilloy, Valentin
Durand, Geoffroy
Voegele, Catherine
Ndow, Gibril
d'Alessandro, Umberto
Brochier-Armanet, Céline
Alain, Sophie
Le Calvez-Kelm, Florence
Hall, Janet
Zoulim, Fabien
Mendy, Maimuna
Thursz, Mark
Lemoine, Maud
Chemin, Isabelle
author_sort Cohen, Damien
collection PubMed
description BACKGROUND & AIMS: Although HBV is a major cause of death in Africa, its genetic variability has been poorly documented. This study aimed to address whether HBV genotype and surface gene variants are associated with HBV-related liver disease in The Gambia. METHODS: We conducted a case-control study nested in the Prevention of Liver Fibrosis and Cancer in Africa programme. Consecutive treatment-naive patients with chronic HBV infection and detectable viral load were recruited: 211 controls with no significant liver disease and 91 cases (56 cirrhosis and 35 HCC cases). HBV genotypes and surface gene variants were determined by Sanger sequencing or next-generation sequencing (NGS) in serum DNA. Aflatoxin B1 (AFB1)-specific codon 249 TP53 mutation was determined by NGS in circulating cell-free plasma DNA. RESULTS: In phylogenetic analysis, 85% of individuals carried HBV genotype E, 14% genotype A, and 1% A/E recombinant viruses. Surface gene variants were more frequently observed in cases (43% and 57% in cirrhosis and HCC cases, respectively) than controls (25%; p <0.001), with preS2 deletions between nucleotides 38–55 (preS2Δ38–55) being the main genetic variant detected. In multivariable analysis, HBeAg seropositivity, low HBsAg levels, and HDV seropositivity were significantly associated with cirrhosis and HCC, whilst older age, higher viral load, genotype A, preS2Δ38–55, and AFB1 exposure were only associated with HCC. There was a multiplicative joint effect of preS2Δ38–55 variants with HBeAg seropositivity (odds ratio [OR] 43.1 [10.4–177.7]), high viral load >2,000 IU/ml (OR 22.7 [8.0–64.9]), HBsAg levels <10,000 IU/ml (OR 19.0 [5.5–65.3]), and AFB1 exposure (OR 29.3 [3.7–230.4]) on HCC risk. CONCLUSIONS: This study identified a hotspot for HBV preS2 deletions as a strong independent factor for HCC in The Gambia, with HBV genotypes and AFB1 exposure contributing to the high liver cancer risk. LAY SUMMARY: Although HBV-related liver disease is highly prevalent in sub-Saharan Africa, the associated virological characteristics are poorly studied. Using clinical data from African patients chronically infected with HBV, an assessment of the virological variability (genotypes and mutations) and exposure to AFB1, a toxin often contaminating food, was carried out. Our results show that HBV genotypes, the presence of a highly prevalent mutant form of HBV, and AFB1 exposure contribute to the high liver cancer risk in this population.
format Online
Article
Text
id pubmed-7452365
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74523652020-09-04 Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma Cohen, Damien Ghosh, Sumantra Shimakawa, Yusuke Ramou, Njie Garcia, Pierre Simon Dubois, Anaëlle Guillot, Clément Kakwata-Nkor Deluce, Nora Tilloy, Valentin Durand, Geoffroy Voegele, Catherine Ndow, Gibril d'Alessandro, Umberto Brochier-Armanet, Céline Alain, Sophie Le Calvez-Kelm, Florence Hall, Janet Zoulim, Fabien Mendy, Maimuna Thursz, Mark Lemoine, Maud Chemin, Isabelle JHEP Rep Research Article BACKGROUND & AIMS: Although HBV is a major cause of death in Africa, its genetic variability has been poorly documented. This study aimed to address whether HBV genotype and surface gene variants are associated with HBV-related liver disease in The Gambia. METHODS: We conducted a case-control study nested in the Prevention of Liver Fibrosis and Cancer in Africa programme. Consecutive treatment-naive patients with chronic HBV infection and detectable viral load were recruited: 211 controls with no significant liver disease and 91 cases (56 cirrhosis and 35 HCC cases). HBV genotypes and surface gene variants were determined by Sanger sequencing or next-generation sequencing (NGS) in serum DNA. Aflatoxin B1 (AFB1)-specific codon 249 TP53 mutation was determined by NGS in circulating cell-free plasma DNA. RESULTS: In phylogenetic analysis, 85% of individuals carried HBV genotype E, 14% genotype A, and 1% A/E recombinant viruses. Surface gene variants were more frequently observed in cases (43% and 57% in cirrhosis and HCC cases, respectively) than controls (25%; p <0.001), with preS2 deletions between nucleotides 38–55 (preS2Δ38–55) being the main genetic variant detected. In multivariable analysis, HBeAg seropositivity, low HBsAg levels, and HDV seropositivity were significantly associated with cirrhosis and HCC, whilst older age, higher viral load, genotype A, preS2Δ38–55, and AFB1 exposure were only associated with HCC. There was a multiplicative joint effect of preS2Δ38–55 variants with HBeAg seropositivity (odds ratio [OR] 43.1 [10.4–177.7]), high viral load >2,000 IU/ml (OR 22.7 [8.0–64.9]), HBsAg levels <10,000 IU/ml (OR 19.0 [5.5–65.3]), and AFB1 exposure (OR 29.3 [3.7–230.4]) on HCC risk. CONCLUSIONS: This study identified a hotspot for HBV preS2 deletions as a strong independent factor for HCC in The Gambia, with HBV genotypes and AFB1 exposure contributing to the high liver cancer risk. LAY SUMMARY: Although HBV-related liver disease is highly prevalent in sub-Saharan Africa, the associated virological characteristics are poorly studied. Using clinical data from African patients chronically infected with HBV, an assessment of the virological variability (genotypes and mutations) and exposure to AFB1, a toxin often contaminating food, was carried out. Our results show that HBV genotypes, the presence of a highly prevalent mutant form of HBV, and AFB1 exposure contribute to the high liver cancer risk in this population. Elsevier 2020-07-11 /pmc/articles/PMC7452365/ /pubmed/32904132 http://dx.doi.org/10.1016/j.jhepr.2020.100144 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Cohen, Damien
Ghosh, Sumantra
Shimakawa, Yusuke
Ramou, Njie
Garcia, Pierre Simon
Dubois, Anaëlle
Guillot, Clément
Kakwata-Nkor Deluce, Nora
Tilloy, Valentin
Durand, Geoffroy
Voegele, Catherine
Ndow, Gibril
d'Alessandro, Umberto
Brochier-Armanet, Céline
Alain, Sophie
Le Calvez-Kelm, Florence
Hall, Janet
Zoulim, Fabien
Mendy, Maimuna
Thursz, Mark
Lemoine, Maud
Chemin, Isabelle
Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma
title Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma
title_full Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma
title_fullStr Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma
title_full_unstemmed Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma
title_short Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma
title_sort hepatitis b virus pres2δ38–55 variants: a newly identified risk factor for hepatocellular carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452365/
https://www.ncbi.nlm.nih.gov/pubmed/32904132
http://dx.doi.org/10.1016/j.jhepr.2020.100144
work_keys_str_mv AT cohendamien hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT ghoshsumantra hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT shimakawayusuke hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT ramounjie hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT garciapierresimon hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT duboisanaelle hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT guillotclement hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT kakwatankordelucenora hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT tilloyvalentin hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT durandgeoffroy hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT voegelecatherine hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT ndowgibril hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT dalessandroumberto hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT brochierarmanetceline hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT alainsophie hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT lecalvezkelmflorence hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT halljanet hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT zoulimfabien hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT mendymaimuna hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT thurszmark hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT lemoinemaud hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma
AT cheminisabelle hepatitisbviruspres2d3855variantsanewlyidentifiedriskfactorforhepatocellularcarcinoma